Psoriasis induced by infliximab.

Detalhes bibliográficos
Autor(a) principal: Fernandes, Iolanda C
Data de Publicação: 2011
Outros Autores: Torres, Tiago, Sanches, Madalena, Velho, Glória, Lago, Paula, Selores, Manuela
Tipo de documento: Artigo
Idioma: por
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/1534
Resumo: Recently, the tumor necrosis factor-α inhibitors (anti-TNF-α) have been extensively used in clinical practice, in the treatment of several immune-mediated disorders, such as inflammatory bowel diseases, rheumatoid arthritis and more recently in psoriasis.A 35-year-old woman, suffering from Crohn's disease, diagnosed in 1994, successfully treated with infliximab at the dosage of 5 mg/Kg every 8 weeks, since 10 months ago, was referred to our Dermatology Department due to the development of erythematic-scaling confluent plaques on the scalp, back and umbilical fold. The skin biopsy confirmed the clinical diagnosis of psoriasis. Given the severity of the skin lesions and its relation with the anti-TNF-α, we decided to discontinue infliximab.Psoriasis results from the combination of polygenic predisposition and several triggering factors. Paradoxically, it has been described an increase of psoriasis induced by biologic agents. The pathogenic mechanism of such paradoxical effect has not yet been clearly elucidated.
id RCAP_baac317da4dd2af410e5db2b4da6eb15
oai_identifier_str oai:ojs.www.actamedicaportuguesa.com:article/1534
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Psoriasis induced by infliximab.Psoríase induzida por infliximab.Recently, the tumor necrosis factor-α inhibitors (anti-TNF-α) have been extensively used in clinical practice, in the treatment of several immune-mediated disorders, such as inflammatory bowel diseases, rheumatoid arthritis and more recently in psoriasis.A 35-year-old woman, suffering from Crohn's disease, diagnosed in 1994, successfully treated with infliximab at the dosage of 5 mg/Kg every 8 weeks, since 10 months ago, was referred to our Dermatology Department due to the development of erythematic-scaling confluent plaques on the scalp, back and umbilical fold. The skin biopsy confirmed the clinical diagnosis of psoriasis. Given the severity of the skin lesions and its relation with the anti-TNF-α, we decided to discontinue infliximab.Psoriasis results from the combination of polygenic predisposition and several triggering factors. Paradoxically, it has been described an increase of psoriasis induced by biologic agents. The pathogenic mechanism of such paradoxical effect has not yet been clearly elucidated.Recently, the tumor necrosis factor-α inhibitors (anti-TNF-α) have been extensively used in clinical practice, in the treatment of several immune-mediated disorders, such as inflammatory bowel diseases, rheumatoid arthritis and more recently in psoriasis.A 35-year-old woman, suffering from Crohn's disease, diagnosed in 1994, successfully treated with infliximab at the dosage of 5 mg/Kg every 8 weeks, since 10 months ago, was referred to our Dermatology Department due to the development of erythematic-scaling confluent plaques on the scalp, back and umbilical fold. The skin biopsy confirmed the clinical diagnosis of psoriasis. Given the severity of the skin lesions and its relation with the anti-TNF-α, we decided to discontinue infliximab.Psoriasis results from the combination of polygenic predisposition and several triggering factors. Paradoxically, it has been described an increase of psoriasis induced by biologic agents. The pathogenic mechanism of such paradoxical effect has not yet been clearly elucidated.Ordem dos Médicos2011-12-30info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/1534oai:ojs.www.actamedicaportuguesa.com:article/1534Acta Médica Portuguesa; Vol. 24 (2011): Suplemento 3; 709-12Acta Médica Portuguesa; Vol. 24 (2011): Suplemento 3; 709-121646-07580870-399Xreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPporhttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/1534https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/1534/1119Fernandes, Iolanda CTorres, TiagoSanches, MadalenaVelho, GlóriaLago, PaulaSelores, Manuelainfo:eu-repo/semantics/openAccess2022-12-20T10:58:03Zoai:ojs.www.actamedicaportuguesa.com:article/1534Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T16:17:12.911824Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Psoriasis induced by infliximab.
Psoríase induzida por infliximab.
title Psoriasis induced by infliximab.
spellingShingle Psoriasis induced by infliximab.
Fernandes, Iolanda C
title_short Psoriasis induced by infliximab.
title_full Psoriasis induced by infliximab.
title_fullStr Psoriasis induced by infliximab.
title_full_unstemmed Psoriasis induced by infliximab.
title_sort Psoriasis induced by infliximab.
author Fernandes, Iolanda C
author_facet Fernandes, Iolanda C
Torres, Tiago
Sanches, Madalena
Velho, Glória
Lago, Paula
Selores, Manuela
author_role author
author2 Torres, Tiago
Sanches, Madalena
Velho, Glória
Lago, Paula
Selores, Manuela
author2_role author
author
author
author
author
dc.contributor.author.fl_str_mv Fernandes, Iolanda C
Torres, Tiago
Sanches, Madalena
Velho, Glória
Lago, Paula
Selores, Manuela
description Recently, the tumor necrosis factor-α inhibitors (anti-TNF-α) have been extensively used in clinical practice, in the treatment of several immune-mediated disorders, such as inflammatory bowel diseases, rheumatoid arthritis and more recently in psoriasis.A 35-year-old woman, suffering from Crohn's disease, diagnosed in 1994, successfully treated with infliximab at the dosage of 5 mg/Kg every 8 weeks, since 10 months ago, was referred to our Dermatology Department due to the development of erythematic-scaling confluent plaques on the scalp, back and umbilical fold. The skin biopsy confirmed the clinical diagnosis of psoriasis. Given the severity of the skin lesions and its relation with the anti-TNF-α, we decided to discontinue infliximab.Psoriasis results from the combination of polygenic predisposition and several triggering factors. Paradoxically, it has been described an increase of psoriasis induced by biologic agents. The pathogenic mechanism of such paradoxical effect has not yet been clearly elucidated.
publishDate 2011
dc.date.none.fl_str_mv 2011-12-30
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/1534
oai:ojs.www.actamedicaportuguesa.com:article/1534
url https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/1534
identifier_str_mv oai:ojs.www.actamedicaportuguesa.com:article/1534
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/1534
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/1534/1119
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Ordem dos Médicos
publisher.none.fl_str_mv Ordem dos Médicos
dc.source.none.fl_str_mv Acta Médica Portuguesa; Vol. 24 (2011): Suplemento 3; 709-12
Acta Médica Portuguesa; Vol. 24 (2011): Suplemento 3; 709-12
1646-0758
0870-399X
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1817553496588681216